Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin, Light, and MTNR1B Genotype on Glucose Control (Study 2)
NCT03464084Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Feb 2018
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of melatonin in type 2 diabetes mellitus (T2DM), sponsored by Brigham and Women's Hospital. Primary endpoint: change in glucose tolerance at Day 1. Started Feb 2018; status: completed.
02
Drugs
melatonin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03464084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03464084.